Selective Androgen Receptor Modulator — Not Recommended
Matrix Advisory
SARMs are not recommended. Source data indicates poor risk-to-reward. Testosterone under medical supervision is the safer, more effective option. Even as the "mildest" SARM, the risk-to-reward isn't there.
Ostarine (MK-2866, Enobosarm) is the mildest and most widely used SARM, originally developed for muscle wasting and osteoporosis. It is often marketed as a "safe" entry-level SARM. Source assessment: "Garbage. Risk-to-reward isn't there." Despite being milder than LGD-4033 or RAD-140, it still suppresses natural testosterone and delivers marginal results compared to supervised TRT.
Selectively binds androgen receptors in muscle and bone tissue, promoting modest anabolic effects. Considered the weakest SARM in terms of both gains and suppression — but suppression still occurs. Users often end up needing PCT for a compound that delivered minimal results in the first place.
For Reference Only
Matrix does not recommend Ostarine. These doses are provided solely for harm-reduction awareness. Testosterone under medical supervision is the preferred protocol.
| Parameter | Details |
|---|---|
| Starting Dose | 10 mg daily |
| Moderate Dose | 20 mg daily |
| Route | Oral |
| Cycle Length | 6–8 weeks |
| Suppression | Still suppresses — milder than LGD/RAD but hormonal impact is real |
Mandatory Requirements
If used despite this advisory, the following are non-negotiable:
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any protocol.